ALERT:

Clinical Trial

Ovarian Cancer Clinical Trial 20203103

[LCID Study Number: 20203103]

A Multicenter Phase 3, Double-Blind, Placebo-Controlled Study Comparing Chemo-Immunotherapy (Paclitaxel-Carboplatin-Oregovomab) vs. Chemotherapy (Paclitaxel-Carboplatin-Placebo) in Patients With Advanced Epithelial Ovarian, Fallopian Tube or Peritoneal Carcinoma (FLORA-5)

The purpose of this study is to compare the safety and efficacy of oregovomab versus placebo, administered in combination with specific cycles of a standard six-cycle chemotherapy regimen (paclitaxel and carboplatin), for the treatment of subjects with newly diagnosed advanced ovarian cancer who have undergone optimal debulking.

Disease/Condition: Ovarian Cancer

Department: Hematology and Oncology

Location: Lahey Hospital & Medical Center (Burlington)

Primary Contact Email: cancerclinicaltrials@lahey.org

Primary Contact Phone: 781-744-3421

Clinical Trial Details

View NCT ID 04498117 on ClinicalTrials.gov

Protocol #: 20203103

Principal Investigator(s): Corrine Zarwan

Trial Phase: Sponsor Initiated Study Phase 3